Navigation Links
Chemotherapy Induced Neutropenia (CIN) - Market Insights, Epidemiology and Market Forecast - 2023
Date:3/28/2017

NEW YORK, March 28, 2017 /PRNewswire/ -- "Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW).

The Report covers the therapeutics market revenue, treatment practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report provides the historical and forecasted data of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 cancer indications till 2023.

The report covers the number of patients for 10 cancer indications (i.e. Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin's disease and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse event of the chemotherapies of respective cancers. Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991.

Its PEGylated formulation, Neulasta was later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute to majority of the market size, of CIN. However, New Chemical Entities are expected to launch in the near future. According to DelveInsight, the Global Market size of CIN in 2016 was USD 3.67 Billion.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Read the full report: http://www.reportlinker.com/p04800430-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chemotherapy-induced-neutropenia-cin---market-insights-epidemiology-and-market-forecast---2023-300430694.html


'/>"/>
SOURCE Reportlinker
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Growth of 5.41%, 2017-2021 With GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Tesaro Dominating
2. BeyondSpring Presents Encouraging Clinical Data for Lead Asset on Chemotherapy-Induced Neutropenia at 2016 ASH Annual Meeting
3. Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy
4. Polaris Groups ADI-PEG 20 Shows Robust Clinical Activity in Malignant Plural Mesothelioma and NSCLC When Combined with Standard First Line Chemotherapy Regimen
5. DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC)
6. Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer
7. CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers
8. CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium
9. Kaiser Permanente Study Finds Shingles Vaccine Remains Effective After Chemotherapy
10. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
11. Acacia Pharma Initiates Phase II Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2020)... ... 2020 , ... Dignitana AB , world leader in scalp cooling innovation, ... sponsor three signature events in 2020 with Susan G. Komen®. The sponsorship extends Dignitana’s ... the Cure® and MORE THAN PINK Walk® events in key Dignitana markets throughout year. ...
(Date:2/14/2020)... ... February 14, 2020 , ... Group Health Dental , ... that conveniently offers a complete range of dental services under one roof. The midtown ... Dentist by Find Local Doctors . Find Local Doctors is a trusted online ...
(Date:2/13/2020)... (PRWEB) , ... February 13, 2020 , ... The global ... up 2.9% from the estimated value of $93.9 billion in 2010, according to a ... , “Growth in this market is driven by an aging population ...
Breaking Medicine Technology:
(Date:2/21/2020)... ... 2020 , ... Used for years as a natural facial ... a viable replacement for invasive cosmetic surgery, such as breast augmentation. According to ... market leader for the expected robust growth of autologous fat grafting procedures. At ...
(Date:2/20/2020)... (PRWEB) , ... February 20, 2020 , ... R3 Stem ... Program was able to complete 70 complimentary stem cell procedures on military ... regenerative therapies at no cost. , At the R3 Stem Cell Training Course for ...
(Date:2/19/2020)... ... February 19, 2020 , ... ... application deadline for its new Lifestyle Medicine Residency Curriculum (LMRC). The curriculum is ... into medical residency programs. Driven by resident involvement, the curriculum has included ...
(Date:2/19/2020)... ... 19, 2020 , ... Nvision Biomedical Technologies , a ... for lower extremities at the American College of Foot and Ankle Surgeons Annual ... Ti Stand-Alone Osteotomy Wedge Fixation System will lead Nvision's innovative showcase. The Trigon ...
(Date:2/15/2020)... (PRWEB) , ... February 14, 2020 , ... ... cleaning products, partnered with Baptist Easley Hospital , a member of Prisma ... patient environments. With PCPLUS, the world-class hospital was able to cut its monthly ...
Breaking Medicine News(10 mins):